Skip to main content
. 2018 Mar 15;15(5):7999–8004. doi: 10.3892/ol.2018.8279

Figure 2.

Figure 2.

Dp44mT and DpC promote the apoptosis of Cal-27, FaDu and SCC-9 cells. DpC (0, 1, 5, 10 and 50 µM) and Dp44mT (0, 1, 5, 10 and 50 µM) were used to treat Cal-27, SCC-9 and FaDu HNSCC cells for 24 h. (A) The apoptotic rate of the Cal-27 cells when treated with DpC (0, 1, 5, 10 and 50 µM) and Dp44mT (0, 1, 5, 10 and 50 µM). (B) The apoptotic rate of the SCC-9 cells when treated with DpC (0, 1, 5, 10 and 50 µM) and Dp44mT (0, 1, 5, 10 and 50 µM). (C) The apoptotic rate of the FaDu cells when treated with DpC (0, 1, 5, 10 and 50 µM) and Dp44mT (0, 1, 5, 10 and 50 µM). The apoptotic rate of the cells increased with the increase of the concentration of DpC and Dp44mT, indicating that DpC and Dp44mT are able to promote the apoptosis of HNSCC cells. The effect of DpC on the apoptosis of HNSCC cells was stronger compared with Dp44mT. *P<0.001. Dp44mT, di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone; DpC, di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone; HNSCC, head and neck squamous cell carcinoma.